| Page 1698 | Kisaco Research
 

Simon Bailey

EVP, Head of Drug Discovery
Plexium

As Head of Drug Discovery at Plexium, Simon oversees the company’s efforts to identify novel protein degrader drugs that address significant unmet medical needs. Simon joined Plexium in 2019 bringing more than 25 years’ experience of medicinal chemistry and small molecule drug discovery leadership experience. From 1995-2015, Simon held positions of increasing responsibility at Pfizer including leading the Diabetes and Oncology Medicinal Chemistry Departments. 

Simon Bailey

EVP, Head of Drug Discovery
Plexium

Simon Bailey

EVP, Head of Drug Discovery
Plexium

As Head of Drug Discovery at Plexium, Simon oversees the company’s efforts to identify novel protein degrader drugs that address significant unmet medical needs. Simon joined Plexium in 2019 bringing more than 25 years’ experience of medicinal chemistry and small molecule drug discovery leadership experience. From 1995-2015, Simon held positions of increasing responsibility at Pfizer including leading the Diabetes and Oncology Medicinal Chemistry Departments. 

 

Andy Pike

Senior DMPK Lead
AstraZeneca

Andy Pike

Senior DMPK Lead
AstraZeneca

Andy Pike

Senior DMPK Lead
AstraZeneca
 

Zhengnian Li

PhD, Post-Doctoral Fellow, Laboratory of Dr. Nathanael Gray
Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School

Zhengnian Li

PhD, Post-Doctoral Fellow, Laboratory of Dr. Nathanael Gray
Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School

Zhengnian Li

PhD, Post-Doctoral Fellow, Laboratory of Dr. Nathanael Gray
Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School
 

Gopal Sapkota

Programme Leader in Protein Phosphorylation
University of Dundee

Gopal Sapkota

Programme Leader in Protein Phosphorylation
University of Dundee

Gopal Sapkota

Programme Leader in Protein Phosphorylation
University of Dundee
 

Frank Mercurio

CSO
BioTheryX

Frank Mercurio

CSO
BioTheryX

Frank Mercurio

CSO
BioTheryX
 

Michael Dabrowski

Co-founder & CEO
Pelago Biocsience

Michael Dabrowski, PhD, co-founder and CEO of Pelago Bioscience. Michael began his Drug Discovery career as an industrial Masters- and PhD-student at Novo Nordisk and worked as a postdoc on Type 2 diabetes. He then developed a long career at AstraZeneca: from senior scientist and technology expert, to project and scientific leader and manager.

Michael Dabrowski

Co-founder & CEO
Pelago Biocsience

Michael Dabrowski

Co-founder & CEO
Pelago Biocsience

Michael Dabrowski, PhD, co-founder and CEO of Pelago Bioscience. Michael began his Drug Discovery career as an industrial Masters- and PhD-student at Novo Nordisk and worked as a postdoc on Type 2 diabetes. He then developed a long career at AstraZeneca: from senior scientist and technology expert, to project and scientific leader and manager. Through his diverse career, Michael has built a vast industry network and accumulated experience in Drug Discovery, from active laboratory activity, assay and test development, personnel manager, project management and overall portfolio responsibilities. Michael’s key strengths and experience are in establishing cross functional collaborations and Business Development.

 

Huib Ovaa

Professor of Chemical Biology of Post Translational Modification
University of Leiden

Huib Ovaa

Professor of Chemical Biology of Post Translational Modification
University of Leiden

Huib Ovaa

Professor of Chemical Biology of Post Translational Modification
University of Leiden
 
Transcription Factor Drug Development
6-9 Jul 2020
VIRTUAL SUMMIT | CEST Timezone
With an increasing number of projects entering the pipeline both clinically and pre-clinically aimed at targeting transcription factors that were previously thought to be “undruggable”, the industry is ready to develop further insight into the commercialization of TF-based therapeutics within cancer and other disease settings. With multiple strategies having entered the clinic from PPI inhibitors, modulators of TF expression, and the first PROTAC-based degraders, it could only be a matter of time before the first therapy enters the market.The inaugural Transcription Factor Drug Development Congress is the first of its kind anywhere in the world! We will bring together leading industry players within large pharma and biotech, along with expert academics in the oncology drug discovery space – providing an open forum to facilitate the sharing of in vitro and in vivo data, as well as build a deeper understanding of transcriptional machinery to make the ‘undruggable’ druggable.Expect to hear strategies to overcome the structural biology, pharmacology, and chemistry obstacles in the design and development of TF-based therapeutics by hearing real success stories in the targeting of transcription factors for therapeutic benefit.Develop further insight into targeting MYC, STAT, and other transcription factors with a role in disease.